- Home
- KPRX vs GIPR Comparison
KPRX vs GIPR Comparison
Compare KPRX & GIPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- GIPR
- Stock Information
- Founded
- KPRX 1998
- GIPR 2015
- Country
- KPRX United States
- GIPR United States
- Employees
- KPRX N/A
- GIPR N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- GIPR Real Estate Investment Trusts
- Sector
- KPRX Health Care
- GIPR Real Estate
- Exchange
- KPRX Nasdaq
- GIPR Nasdaq
- Market Cap
- KPRX 9.1M
- GIPR 8.8M
- IPO Year
- KPRX N/A
- GIPR 2021
- Fundamental
- Price
- KPRX $3.08
- GIPR $1.46
- Analyst Decision
- KPRX Strong Buy
- GIPR Hold
- Analyst Count
- KPRX 1
- GIPR 1
- Target Price
- KPRX $10.00
- GIPR N/A
- AVG Volume (30 Days)
- KPRX 1.3M
- GIPR 19.7K
- Earning Date
- KPRX 05-09-2025
- GIPR 05-15-2025
- Dividend Yield
- KPRX N/A
- GIPR 2.63%
- EPS Growth
- KPRX N/A
- GIPR N/A
- EPS
- KPRX N/A
- GIPR N/A
- Revenue
- KPRX $20,000.00
- GIPR $9,711,058.00
- Revenue This Year
- KPRX N/A
- GIPR N/A
- Revenue Next Year
- KPRX N/A
- GIPR N/A
- P/E Ratio
- KPRX N/A
- GIPR N/A
- Revenue Growth
- KPRX N/A
- GIPR 11.25
- 52 Week Low
- KPRX $2.51
- GIPR $1.43
- 52 Week High
- KPRX $5.55
- GIPR $4.55
- Technical
- Relative Strength Index (RSI)
- KPRX 48.79
- GIPR 35.32
- Support Level
- KPRX $2.90
- GIPR $1.46
- Resistance Level
- KPRX $4.18
- GIPR $1.66
- Average True Range (ATR)
- KPRX 0.26
- GIPR 0.12
- MACD
- KPRX 0.00
- GIPR -0.02
- Stochastic Oscillator
- KPRX 19.12
- GIPR 0.00
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About GIPR Generation Income Properties Inc.
Generation Income Properties Inc is an internally managed real estate investment company focused on acquiring and managing income-producing retail, office and industrial properties net leased to high-quality tenants in markets throughout the United States. Its key source of revenue is the rental income. The company holds properties in Alabama, Arizona, Colorado, the District of Columbia, Florida, Illinois, North Carolina and Virginia.